Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 6/20 | 0.38 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.35 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.34 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.34 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.34 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.34 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.34 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.34 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.34 |
| ▸ | RELA | Q04206 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14782547 | 0.82 | HTR2B (0.38) | HTR2BAVPR1ANPC1MAPTRAB9A | |
| SCHEMBL20292182 | 0.79 | CHRM4 (0.40) | L3MBTL1PARP1 | |
| SCHEMBL9894217 | 0.78 | HTR2B (0.36) | HTR2BPARP1 | |
| SCHEMBL1662947 | 0.78 | RBP4 (0.37) | HTR2B | |
| SCHEMBL17001810 | 0.78 | HTR1D (0.41) | PARP1 | |
| SCHEMBL1662372 | 0.76 | ALDH1A1 (0.37) | HTR2B | |
| SCHEMBL1664729 | 0.75 | HTR2B (0.34) | HTR2B | |
| SCHEMBL6168951 | 0.75 | HTR2B (0.51) | HTR2B | |
| SCHEMBL1664728 | 0.75 | HTR2B (0.40) | HTR2BLMNAL3MBTL1PARP1 | |
| SCHEMBL6166219 | 0.74 | HTR2B (0.49) | HTR2BLMNAL3MBTL1HSD11B1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2491032-B1 | AKT INHIBITORS | LILLY CO ELI (US) | 2014-04-16 | — | — | EP | disclosed |
| US-8436002-B2 | AKT inhibitors | ELI LILLY AND COMPANY (US) | 2013-05-07 | — | — | US | disclosed |
| US-20120149684-A1 | AKT INHIBITORS | ELI LILLY AND COMPANY (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149684-A1 | AKT INHIBITORS | AKT2, PIK3CA, AKT3 | HTR2B 3577/4885AVPR1A 4803/4885LMNA 4267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.